Prebiotic Oligosaccharide Composition for Targeted BSCFA Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing oligosaccharide compositions do not effectively reduce branched short chain fatty acids (BSCFAs) levels, which are associated with conditions such as damaged colon epithelium, prostatic hyperplasia, and metabolic syndrome, and do not provide long-lasting health benefits to consumers.
Innovation Solution
A composition comprising at least 8 wt % Gal-(β1-3)-Gal-(β1-4)-Xa, at least 3 wt % Gal-(β1-3)-Gal-(β1-3)-Xb, and at least 5 wt % Gal-(β1-3)-Gal-(β1-2)-Xc, where Xa, Xb, and Xc are monosaccharides, to modulate BSCFA levels and improve gut microbiota health.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If known GOS prebiotic products containing a mixture of many oligosaccharide compounds in varying proportions are used, then some beneficial results in improving health are achieved, but the effectiveness in reducing BSCFA levels is insufficient and long-lasting benefits are not provided
Solution Approach 1:
The patent applies local quality by specifying precise proportions of different oligosaccharide compounds within the GOS mixture. Rather than using a random or uniform composition, the invention defines specific ranges for Gal-(β1-3)-Gal-(β1-4)-Glc, Gal-(β1-3)-Gal-(β1-3)-Glc, and Gal-(β1-3)-Gal-(β1-2)-Glc to optimize BSCFA reduction while maintaining manufacturability.
Solution Approach 2:
The patent employs parameter changes by adjusting the compositional parameters of the oligosaccharide mixture. Specifically, it defines weight percentage ranges for different oligosaccharide compounds (e.g., at least 8 wt% Gal-(β1-3)-Gal-(β1-4)-Glc, at least 3 wt% Gal-(β1-3)-Gal-(β1-3)-Glc, at least 5 wt% Gal-(β1-3)-Gal-(β1-2)-Glc) to achieve superior BSCFA reduction compared to conventional GOS products.
2Quantity of substance
If a diet rich in dietary fiber/prebiotics is consumed, then bacterial abundance and gut microbiome gene richness are increased, but the specific reduction of BSCFA levels is not achieved
Solution Approach 1:
The patent applies local quality by designing a prebiotic composition with specific oligosaccharide structures and proportions that selectively target BSCFA reduction. The defined composition (Gal-(β1-3)-Gal-(β1-4)-Glc, Gal-(β1-3)-Gal-(β1-3)-Glc, and Gal-(β1-3)-Gal-(β1-2)-Glc in specific ratios) creates localized beneficial effects on BSCFA metabolism while supporting overall gut microbiome health.
Solution Approach 2:
The patent uses specific oligosaccharide compounds as intermediaries that mediate between general prebiotic effects and specific BSCFA reduction. These engineered GOS compounds act as selective substrates that modulate gut microbiota metabolism to reduce BSCFA production while maintaining or enhancing beneficial bacterial populations.
3Reliability
If GOS products with higher proportions of beneficial oligosaccharides are developed, then effectiveness in reducing BSCFA levels is improved, but manufacturing complexity and cost may increase
Solution Approach 1:
The patent employs parameter changes by defining practical weight percentage ranges for different oligosaccharide compounds that balance effectiveness with manufacturability. The specified composition (at least 8 wt% Gal-(β1-3)-Gal-(β1-4)-Glc, at least 3 wt% Gal-(β1-3)-Gal-(β1-3)-Glc, at least 5 wt% Gal-(β1-3)-Gal-(β1-2)-Glc) represents optimized parameters that achieve superior BSCFA reduction while remaining feasible for industrial production.
Solution Approach 2:
The patent applies composite materials by creating a engineered GOS composition that combines multiple oligosaccharide compounds in specific proportions. This composite approach (mixing Gal-(β1-3)-Gal-(β1-4)-Glc, Gal-(β1-3)-Gal-(β1-3)-Glc, and Gal-(β1-3)-Gal-(β1-2)-Glc) leverages the synergistic effects of different oligosaccharide structures to achieve enhanced BSCFA reduction while maintaining manufacturing efficiency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively reduces BSCFA levels, addressing associated conditions and enhancing gut microbiota health, particularly in athletes and individuals on high protein diets, with systemic benefits and improved endurance.
Implementation Method 1
Prebiotics are non-digestible dietary fibers that resist digestion and absorption until they reach the large intestine where they are fermented by members of the gut microbiome. As a byproduct of this fermentation, they produce lactic acid and short-chain fatty acids (SCFAs)
Data Source
AI summary
A prebiotic oligosaccharide composition for use in reducing branched short chain fatty acids (BSCFAs). The composition comprises oligosaccharide compounds, for example galactooligosaccharide compounds, which includes: (a) at least 8 wt % Gal-(β1-3)-Gal-(β1-4)-Xa; (b) at least 3 wt % Gal-(β1-3)-Gal-(β1-3)-Xb; and (c) at least 5 wt % Gal-(β1-3)-Gal-(β1-2)-Xc, based on the total weight of oligosaccharide compounds present in the composition; wherein Xa, Xb and Xc are each independently selected from monosaccharides. These compositions contain relatively high amounts of the oligosaccharide compounds (a), (b) and (c) and a relatively high amount of β1-3 Gal-Gal linkages, compared to known oligosaccharide compositions. The present invention also relates to a composition comprising oligosaccharide compounds for administration to the athletes and/or sports persons who are undergoing and/or are about to undergo physical training, and in particular those athletes and/or sports person on a high protein diet. A method of preparing said composition and the use of said composition as a dietary supplement or a medicament are also disclosed.